This comparative effectiveness study examines whether differential censoring could explain the inconsistent results in trials investigating the addition of programmed cell death 1 protein/programmed cell death 1 ligand 1 inhibitors to platinum-based chemotherapy for advanced urothelial carcinoma. This evidence concerns the gene PDCD1 and urothelial carcinoma.